Apex Biosciences Pte Ltd. has identified phosphodiesterase PDE4B inhibitors reported to be useful for the treatment of cancer, neurological disorders, inflammatory bowel disease, skin inflammation, lung inflammation, eye inflammation and inflammatory joint diseases.
Haisco Pharmaceutical Group Co. Ltd. has synthesized soluble guanylate cyclase (sGC) activators reported to be useful for the treatment of cardiovascular, renal and respiratory disorders.
Relay Therapeutics Inc. has disclosed compounds acting as phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer and PIK3CA-related overgrowth spectrum (PROS).
Podium Bio Ltd. has described compounds acting as apolipoprotein L1 (APOL1) inhibitors reported to be useful for the treatment of chronic kidney disease, focal segmental glomerulosclerosis, HIV-associated nephropathy, microalbuminuria, renal disorders and lupus nephritis.
Inventisbio Co. Ltd. and Inventisbio LLC have divulged Werner syndrome helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Jazz Pharmaceuticals Ireland Ltd. has identified compounds acting as GTPase KRAS and its mutant inhibitors reported to be useful for the treatment of cancer.
Insmed Inc. has synthesized cathepsin C (dipeptidyl peptidase I) inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, asthma, cancer, chronic rhinosinusitis, heart failure, inflammatory bowel disease, psoriasis and thrombosis, among others.
Certa Therapeutics Pty Ltd. has disclosed ovarian cancer G-protein coupled receptor 1 (GPR68; OGR1) antagonists reported to be useful for the treatment of cancer, inflammation and fibrosis.
UCB SA has divulged compounds acting as NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of inflammation, injury, neurodegeneration, and eye, autoimmune and neurological disorders, among others.
RSS